Skip to main content
Contact Us
Subscribe
E-Edition
93°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
5.065
-0.155 (-2.97%)
Streaming Delayed Price
Updated: 3:33 PM EDT, Jul 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
December 09, 2024
Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore®
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
December 09, 2024
Via
Benzinga
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
December 09, 2024
Via
Benzinga
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
December 09, 2024
Prolaris Remains a Long-Standing Fixture in the Guidelines for 10th Year Running
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Where Myriad Genetics Stands With Analysts
November 18, 2024
Via
Benzinga
Analyst Expectations For Myriad Genetics's Future
September 19, 2024
Via
Benzinga
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
November 20, 2024
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
November 19, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
November 14, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
August 13, 2024
Via
Benzinga
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
November 13, 2024
SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
November 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
November 07, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
November 04, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
November 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 01, 2024
Via
Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
November 01, 2024
Via
Benzinga
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
October 30, 2024
Management will also participate in two upcoming investor healthcare conferences
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
October 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
October 15, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
October 08, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
October 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
October 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
September 18, 2024
MyRisk®, FirstGene®, Prequel®, and Foresight® studies among 10 datasets to be shared by Myriad
From
Myriad Genetics, Inc.
Via
GlobeNewswire
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
September 05, 2024
Via
Benzinga
Myriad Genetics to Host Investor Event on October 9, 2024
September 05, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
August 21, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
August 13, 2024
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81.
Via
Investor's Business Daily
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
MYGN stock results show that Myriad Genetics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.